Literature DB >> 20353398

Virus-like particles as particulate vaccines.

Luigi Buonaguro1, Maria L Tornesello, Franco M Buonaguro.   

Abstract

Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. Particulate structures, indeed, represent a very efficient system for delivering antigens to antigen presenting cells (APC) which, in turn, trigger and amplify the adaptive immune response. The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20353398     DOI: 10.2174/157016210791208659

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  19 in total

1.  Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Luisa Visciano; Hanne Andersen; Mark Lewis; Ranajit Pal; Maria Lina Tornesello; Ulf Schroeder; Jorma Hinkula; Britta Wahren; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

2.  Novel antigen delivery systems.

Authors:  Maria Trovato; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2015-08-12

3.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

Review 4.  Advances in virus-like particle vaccines for filoviruses.

Authors:  Kelly L Warfield; M Javad Aman
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Immunogenicity of recombinant human bocavirus-1,2 VP2 gene virus-like particles in mice.

Authors:  Zhong-Hua Deng; Ye-Xia Hao; Li-Hong Yao; Zhi-Ping Xie; Han-Chun Gao; Le-Yun Xie; Li-li Zhong; Bing Zhang; You-De Cao; Zhao-Jun Duan
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

6.  Effects of adjuvants on IgG subclasses elicited by virus-like particles.

Authors:  Maria Luisa Visciano; Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  J Transl Med       Date:  2012-01-05       Impact factor: 5.531

Review 7.  Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.

Authors:  Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

8.  Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain.

Authors:  Wu Ou; Josie Delisle; Jerome Jacques; Joanna Shih; Graeme Price; Jens H Kuhn; Vivian Wang; Daniela Verthelyi; Gerardo Kaplan; Carolyn A Wilson
Journal:  Virol J       Date:  2012-01-25       Impact factor: 4.099

9.  Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.

Authors:  Kelly L Warfield; John M Dye; Jay B Wells; Robert C Unfer; Frederick W Holtsberg; Sergey Shulenin; Hong Vu; Dana L Swenson; Sina Bavari; M Javad Aman
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

10.  HIV p24 as scaffold for presenting conformational HIV Env antigens.

Authors:  Maria Tagliamonte; Daniela Marasco; Alessia Ruggiero; Angelo De Stradis; Maria Lina Tornesello; Maxim Totrov; Franco Maria Buonaguro; Luigi Buonaguro
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.